Called the "Ccheck Prostate Cancer Confirmation" test, Anixa's assay integrates flow cytometry and machine learning to identify evidence of cancer in a person's bloodstream.
Since 2016, the VHA has routinely profiled molecular features in advanced cancers from vets in its care, even in rural locales, though challenges remain.
The VA decided to bring this testing in house to streamline and standardize the process for doctors and gauge markers that are relevant to the veteran population.
The program is supported via a $25 million gift from philanthropist Denny Sanford and matching contributions fundraised by Sanford Health.
The contract covers all of Foundation Medicine's genomic profiling tests, including FoundationOne CDx, FoundationOne Liquid, and FoundationOne Heme.
The five-year federal supply contract is for the company's Steripath Initial Specimen Diversion Device, which virtually eliminates blood culture contamination.
The $12 million PRIME study will involve 2,000 veterans with major depressive disorder and 250 healthcare providers across 21 VA medical centers.
The test analyzes clinically relevant genetic variants for 14 genes related to certain pain and mental health medication responses to help guide clinicians' prescribing decisions.
Advanced cancer patients at the VA will now have access to the company's blood-based PlasmaSelect 64 test as well as the CancerSelect 125 tissue test.
The partners have formed a public/private partnership to foster collaboration and data integration between different institutes researching brain trauma.